Hemorrhoid Treatment Market Size, Share & Industry Analysis, By Product Type (Suppository, Sprays, Creams & Ointments, and Others) By Drug Class (Non-steroidal Anti-inflammatory Drugs (NSAIDs), Local Anesthetics, Corticosteroids, and Others) By Type (Internal {Grade I, Grade II, Grade III, and Grade IV}, and External) By Distribution Channel (Hospital Pharmacy, Drug Stores & Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2024-2032

The global hemorrhoid treatment market size was valued at USD 1.03 billion in 2023. The market is projected to grow from USD 1.08 billion in 2024 to USD 1.74 billion by 2032, exhibiting a CAGR of 6.1% during the forecast period.

Hemorrhoid is a condition in which the veins of the rectum and anus get swollen and inflamed, causing discomfort and bleeding. Hemorrhoids are a very common condition that affects millions of people worldwide and can be caused by factors such as straining during bowel movements, prolonged sitting, obesity, pregnancy, and chronic constipation. They are of two types: internal and external. The internal hemorrhoids, which lie inside the rectum, are usually painless but may cause bleeding during bowel movements. External hemorrhoids are located under the skin around the anus and can cause pain, discomfort, swelling, and itching. As the prevalence of hemorrhoids increases and the associated pain and discomfort rise, there is a greater adoption of hemorrhoid treatment products.

• For instance, as per an article published by TaCa Healthcare, a recent survey stated that India has one of the highest rates of piles in the world. The study showed that approximately 11.0% of the population suffers from piles, with a higher prevalence in urban areas. The condition is more common in men than in women and the risk increases with age.

Additionally, the presence of key players in the market such as Church & Dwight Co., Inc., Haleon Group of Companies, Sebela Pharmaceuticals, and others with advanced product offerings for the treatment of hemorrhoids over-the-counter (OTC) and prescription boosts the adoption of the products and bolsters the market’s growth.

MARKET DYNAMICS

Market Drivers

Rising Prevalence of Hemorrhoids to Propel Market Growth

The increasing prevalence of hemorrhoids is one of the most prominent drivers of the market. Hemorrhoids are a common gastrointestinal condition that occurs when there is extra pressure on the anus and lower rectum veins.

• For instance, according to an article published by the National Institutes of Health (NIH) in 2021, the estimated worldwide prevalence of hemorrhoids in the general population was estimated to be 4.4%.

The increase in the prevalence of the disease among the geriatric population, coupled with poor hygiene and sanitary conditions in lower economic countries will drive the demand for more cost-effective treatment options to control and manage associated symptoms.

Growing Access to Over-the-Counter (OTC) Drugs for Hemorrhoids Treatment to Boost Market Growth 

The rising availability of OTC drugs for the treatment of hemorrhoids is responsible for driving the hemorrhoid disease treatment market growth. The formulations used for the disease treatment are easily available without prescription and are convenient to the patients. Hemorrhoid drugs are widely available at drugstores and online pharmacies. Moreover, the strategic initiatives by key players to expand product reach are further propelling global hemorrhoid treatment market growth.

• For instance, in March 2024, Karo Healthcare expanded its presence in Italy by acquiring the rights to the OTC brand Proctosedyl from Bayer. The transaction transferred the dossier ownership to the OTC pharmaceutical Proctosedyl along with the exclusive license to the Proctosedyl trademark in Italy, from Bayer to Karo. This acquisition strengthens Karo’s presence in Italy.  Such presence of branded drugs over the counter boosts the sales and growth of the market.

Market Restraints

Social Stigma and Barriers to Seeking Medical Care to Restrict Market Growth

One of the key factors impeding market growth is the social stigma and barrier to seeking medical care for hemorrhoid treatment. Hemorrhoids are associated with bowel movements and can be a taboo topic, leading to embarrassment and reluctance to discuss and seek treatment.

• For instance, according to an article published by the International Journal of Medicine in Developing Countries in 2022, a cross-sectional study with a self-administered online questionnaire about hemorrhoids was distributed in all regions of Saudi Arabia. A total of 1,431 questionnaires have been submitted by the respondents (with a response rate of 50%). 66.5% cited Stigma and embarrassment as important reasons to avoid visiting the doctor.

Thus, social stigma and lack of reimbursement options are expected to continue impacting market growth during the forecast period. However, counseling and increasing awareness among the population may facilitate the stigma associated with hemorrhoids and encourage more people to seek treatments.

Other Restraints:

Availability of Alternative Treatments:

The presence of alternative treatment options for hemorrhoids is challenging the growth of the market. These alternatives include conservative methods such as softening the stool, pain relievers, and improving bad toileting habits. Office-based methods such as rubber band ligation, infrared coagulation, and sclerotherapy are cost-effective and reduce the recurrence rate of hemorrhoids. Thus, such scenarios shift the focus of patients toward these options and may hamper market growth.

Regulatory Hurdles and Approval Processes:

Currently, hemorrhoid disease has no FDA-approved drugs as companies across the globe need to clear strict regulatory hurdles for the approval of drugs. This process delays the commercialization of new treatments, further limiting market growth during the forecast period. 

Market Challenges

Potential Challenges and Obstacles:

Despite positive trends, the market may face several challenges, including social stigma, embarrassment, and also stringent regulations for pharmaceuticals could delay the introduction of new treatments and hinder innovation.

Insurance Coverage and Reimbursement Policies:

Lack of insurance coverage and reimbursement policies for the drug treatment of hemorrhoids is hampering the growth of the market in lower economic countries.

MARKET TRENDS

Gradual Increase in the Number of Pipeline Candidates for Hemorrhoid Treatment

One of the prevailing trends witnessed in the global market is the rising focus on research and development activities to fulfill the demand for targeted treatments addressing the core symptoms of hemorrhoids. Current treatment options often lack the therapeutic efficiency needed to target the core symptoms of hemorrhoid disease.

Clinical Trials and Their Outcomes:

• For instance, in June 2023, Citius Pharmaceuticals, Inc. demonstrated the results of a Phase 2b clinical study of Halo-Lido (CITI-002), a topical formulation aimed at relieving hemorrhoid symptoms. The trial evaluated the efficacy of the combination product, selecting the appropriate dose and endpoints for a Phase 3 trial. The combination formulation resulted in a great reduction in symptom severity, as reported by patients when compared to individual components alone. Such initiatives by key players to launch targeted treatment options for hemorrhoids will propel the global market from 2024 to 2032.

Other Trends:

Technological Advancements in Hemorrhoid Treatment:

The increasing demand for convenient formulations that offer faster drug delivery and rapid relief from hemorrhoid discomfort is prompting companies to focus on launching new products for patient comfort in the market. For example, the Haleon group of companies launched Preparation H Totables wipes, designed to numb the affected area, reducing inflammation, itching, and swelling.

Impact of COVID-19

The COVID-19 pandemic positively impacted the hemorrhoid treatment market. The positive impact on the market was due to the rise in the number of hemorrhoid patients during the pandemic, driven by a more sedentary lifestyle. Additionally, over-the-counter drugs for hemorrhoid treatment became more accessible, leading to higher sales and revenue generation. However, the market is expected to grow during the forecast period due to rising demand for adequate treatment options and product launches.

Economic Impact

Cost Analysis of Hemorrhoid Treatments:

The management of hemorrhoids comprises conservative treatments such as topical medications and dietary changes to more advanced interventions, including rubber band ligation, sclerotherapy, and surgical procedures.

Economic burden of Untreated Hemorrhoids:

The economic burden of untreated hemorrhoids can be substantial. Untreated patients are more likely to experience severe pain, rectal bleeding, and complications such as thrombosis, resulting in emergency visits and hospitalizations. These incidents result in direct medical costs and contribute to indirect costs such as lost productivity.

Market Opportunities for Cost-Effective Treatments:

Emphasis on telemedicine and at-home treatment options can potentially increase the demand for over-the-counter products that enhance patient adherence to treatment regimens.

Regulatory Landscape:

The regulatory landscape for the market is primarily governed by regulatory bodies such as the FDA in the U.S. and the EMA in Europe. These agencies oversee the approval processes for new treatments, ensuring their safety and efficacy. Manufacturers must comply with stringent manufacturing and labeling requirements, including clinical trial regulations. These regulations significantly impact market entry, often creating barriers that can limit competition and influence pricing strategies within the sector.

SEGMENTATION ANALYSIS

By Product Type

Ease of Application and Higher Adoption of the Creams & Ointments Propelled the Growth of the Creams & Ointments Segment

Based on product type, the market is divided into suppositories, sprays, creams & ointments, and others.

The creams & ointments segment held the lion’s share of the global hemorrhoids treatment market in 2023. The increasing prevalence of the disease across the globe and patients' preference for the use of creams & ointments due to ease of application, non-invasive symptom relief, and easy availability leads to the boosting growth of the segment. Additionally, increasing awareness programs about hemorrhoids are expected to further increase the adoption of these products for treating hemorrhoid symptoms.

• For instance, the American Society of Colon and Rectal Surgeons (ASCRS) celebrates November as Hemorrhoid Awareness Month every year. This provides an ideal opportunity for individuals experiencing pain and discomfort in the anal area to seek medical treatment as many are reluctant to talk about them.

The suppository segment held the second-largest global hemorrhoid treatment market share in 2023. The growth of the segment is augmented by the increasing number of cases associated with internal hemorrhoids and suppositories being preferred for grade I and II hemorrhoid patients for immediate and long-term relief. These factors are propelling the growth of the segment in the market.

Furthermore, the sprays and others segment is expected to grow modestly during the forecast period. Increasing demand for supplementary products for relieving constipation and rising demand for easy and convenient products for rectal application is expected to propel the segment’s growth during 2024-2032.

By Drug Class

Corticosteroids Segment Dominated due to Wide Availability and Benefits Associated with Corticosteroids

Based on drug class, the market is divided into corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), local anesthetics, and others.

The corticosteroids segment held the dominant share of the market in 2023. Corticosteroids such as hydrocortisone are available in various formulations such as cream, ointment, and suppositories. These corticosteroids work by activating natural substances in the skin to reduce swelling, redness, and itching. These benefits promote the adoption of corticosteroids treatments, boosting the growth of the segment.

Additionally, the local anesthetics segment held the second-largest share of the market. Local anesthetics such as lidocaine and pramoxine are used to relieve pain and itching temporarily caused due to hemorrhoids. Key players in the market are offering different formulations of these treatments and raising awareness regarding hemorrhoids in the region.

• For instance, in November 2022, Bayer AG launched a new creative for Germoloids. This hemorrhoid cream brand sits within the U.K. digestive health pillar under the name ‘Numb Your Bum’ to normalize the uncomfortable problem. Such campaigns promote the adoption of products and contribute to the segment’s growth.

The NSAIDs and others segment are expected to grow during the forecast period. The growth of the segment is augmented by the increasing demand for stool softeners, antibiotics, and pain-relieving medication for decreasing the symptoms associated with hemorrhoids. These factors are likely to promote the growth of the segment.

By Type

Internal Segment Dominated owing to Rising Prevalence of Internal Hemorrhoids

Based on type, the market is segmented into internal and external.

The internal segment held a significant share of the market. The internal hemorrhoids are further divided into grades I, II, III, and IV. The rising prevalence of internal hemorrhoids augments the growth of the segment. Additionally, increasing product demand for internal hemorrhoids is expected to propel the growth of the segment in the market.

• For instance, in April 2021, according to the data published by the National Institute of Health, a study was conducted from February to May 2020 to assess the prevalence and associated factors of hemorrhoids among adult patients visiting the surgical outpatient department at the University of Gondar Comprehensive Specialized Hospital (UoGCSH) Northwest Ethiopia. Among 403 study participants, 53 had hemorrhoids, with an overall prevalence of 13.1%. Also, participants having hemorrhoids were classified as grade I to IV, and the prevalence of grade I, II, III, and IV were 34 (64.1%), 12 (22.7%), 6 (11.3%), and 1 (1.9%), respectively. Such a rising number of patients with grade I hemorrhoids is expected to increase the adoption of hemorrhoid treatment products and propel the growth of the segment.

Additionally, the external segment is expected to grow during the forecast period; rising prevalence and increasing product availability for external hemorrhoids are expected to propel the growth of the segment in the market.

By Distribution Channel

Robust Availability of Over-the-counter Products for Hemorrhoids Treatment to Propel the Growth of the Drug Stores & Retail Pharmacy Segment

Based on distribution channel, the market is segmented into drug stores & retail pharmacies, online pharmacies, and hospital pharmacy.

The drugstore and retail pharmacy held a dominant share of the market. The dominant share of the segment is augmented by the wide range of product availability for hemorrhoid over-the-counter (OTC) and increasing patients' preferences for treating hemorrhoids by themselves due to social stigma. Additionally, increasing OTC product launches by key players to propel the segment’s growth.

• In January 2019, Innovus Pharmaceuticals, Inc. launched its Xyralid Suppositories for the reduction of swelling or inflammation of hemorrhoidal tissues and provides pain relief from burning, itching, and discomfort. The product received a Product License Application (PLA) and is available as an over-the-counter (OTC) in Canada.

Hospital pharmacies held the second-largest share of the segment in the market. The shift of patients toward hospitals after initial treatment with OTC products is attributed to the growth of the segment. Hospital pharmacies play a crucial role in meeting the demand for hemorrhoid treatment drugs as many medications for the treatment require a prescription following a thorough examination by trained medical professionals at these institutions.

The online pharmacies segment is expected to grow at the highest CAGR during the forecast period due to the increased adoption of digital pharmaceutical platforms. These platforms offer privacy for sensitive purchases, such as hemorrhoid treatments, and often integrate with telemedicine services. This enables patients to consult with healthcare professionals and obtain prescriptions online further fueling the growth of the global market.

HEMORRHOID TREATMENT MARKET REGIONAL OUTLOOK

The global market is divided into regions, including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

The North America region dominated the hemorrhoid treatment market and was valued at USD 0.46 billion in 2023. In the North America region, U.S. dominated the region’s market. The presence of advanced healthcare facilities and government awareness programs leading towards the country’s growth in the market. Additionally, the overall region’s growth is due to the rising prevalence of hemorrhoids, the presence of advanced healthcare infrastructure, and key players in the market offering advanced product options.

• For instance, according to the Canadian Digestive Health Foundation, around 60%-70% of Canadians are expected to develop hemorrhoids at some point in their lifetime. Such a large patient population is expected to propel the hemorrhoid treatment market growth. Such a substantial number of cases boosts the adoption of hemorrhoid treatment products and thus propel the region’s growth in the market.

Additionally, increasing research and development activities by key players to launch advanced treatments are likely to propel the market growth.

Europe held the second-largest position due to the rising prevalence of hemorrhoids and the strong regulatory environment with the presence of key players with advanced treatment options for hemorrhoids in the region.

• For instance, according to the data published by the Surgical Orthopaedic Practice Association (COPV) Berlin and Brandenburg, in Germany, approximately 3.3 million patients with hemorrhoids are treated by physicians each year. Such a rising number of hospital visits and treated number of patients is expected to propel product demand.

Asia Pacific is expected to grow during the forecast period. The growth of the region is due to the rising patient population and rising awareness programs aimed at reducing the social stigma surrounding hemorrhoids and encouraging people to seek treatment.

• For instance, in November 2022, TaCa Healthcare, an ethical and sustainable health-tech startup, launched the #Let’sTalkPiles campaign. #Let’sTalkPiles campaign aimed to spread awareness about the complications of ignoring piles and motivate people to seek appropriate treatment without any delay.

Despite these efforts, social stigma remains a challenge in the region. However, the region’s rising population and presence of advanced healthcare facilities offer lucrative growth opportunities.

The Middle East & Africa are expected to grow during the forecast period. The growth of the region will be primarily due to the increasing prevalence of hemorrhoids, expansion of healthcare infrastructure, and easy availability of products with convenient applications. Thus, such scenarios are expected to propel the adoption of creams and ointments in the region.

Latin America is expected to grow during the forecast period due to the increasing prevalence of hemorrhoids, which is prompting key players to focus on expanding their footprints in the region.

COMPETITVE LANDSCAPE

KEY INDUSTRY PLAYERS

Key Players Focus on Expanding their Product Offerings to Bolster their Market Position

In 2023, the Haleon Group of Companies is a major player in the market, with a robust product portfolio, strong geographical presence, and strategic activities aimed at expanding its offerings. Other key players in the market include Church & Dwight Co., Inc., AMATO PHARMACEUTICAL PRODUCTS, LTD., Sebela Pharmaceuticals, Bayer AG, Abbott, and Lupin. These companies offer a wide range of product offerings, including various OTC and prescription medications for hemorrhoids treatment, further strengthening their market position across the globe. Strategic initiatives, such as partnerships also contribute to the market growth.

For instance, in February 2024, Church & Dwight Co., Inc. renewed its partnership with DKSH Hong Kong to expand the reach of its Church & Dwight’s Anusol product range in Hong Kong through DKSH agency services.

Future Outlook

Predicted Market Trends and Growth Areas:

The hemorrhoid treatment market is anticipated to experience significant growth over the coming years, driven by factors such as an increasing prevalence of hemorrhoids, heightened awareness regarding preventive healthcare, and advancements in medical technology. The demand for home remedies and over-the-counter treatments will likely rise due to preferred self-management options. Additionally, the integration of telemedicine for consultations and digital platforms for patient education and support will also shape the future landscape, improving accessibility for patients.

Opportunities for Innovation and Investment:

There are numerous opportunities for innovation and investment in the market, including investment in research to develop new, effective pharmacological solutions that can cater to a growing market segment seeking natural alternatives.

Additionally, the integration of technology can improve patient management and offer personalized treatment plans.

Recommendations for Stakeholders

To capitalize on the predicted growth in the market, stakeholders-including manufacturers, healthcare providers, and investors should focus on developing patient-centric solutions that prioritize comfort, convenience, and accessibility. This includes creating personalized at-home care kits and telehealth services.

LIST OF KEY MARKET PLAYERS PROFILED:

• Lupin (India)


• Cipla (India)


• AMATO PHARMACEUTICAL PRODUCTS, LTD. (Japan)


• Church & Dwight Co., Inc. (U.S.)


• Haleon Group of Companies (U.K.)


• Sebela Pharmaceuticals (U.S.)


• Bayer AG (Germany)


• Sanofi (France)


• Abbott (U.S.)


• Sun Pharmaceutical Industries, Inc. (India)

KEY INDUSTRY DEVELOPMENTS:

• September 2024: Haleon Group of Companies agreed to acquire Tianjin TSKF Pharmaceutical Co. Ltd., China. This acquisition aimed to deliver greater control and increased strategic and operational flexibility across the business.


• November 2023: SERVIER MALAYSIA launched emoflon in Malaysia. This ointment is used to treat symptoms associated with hemorrhoidal disease and its complications, such as eczema and anal fissure.


• June 2023: Citius Pharmaceuticals, Inc. reported the results of its Phase 2b clinical study of Halo-Lido (CITI-002), a topical formulation designed to relieve hemorrhoid symptoms.


• June 2021: AMATO PHARMACEUTICAL PRODUCTS, LTD. underwent an acquisition by ROHTO Pharmaceutical Co.,Ltd. This strategic move enabled the company to expand its operations into new markets, leveraging the financial support provided by ROHTO Pharmaceutical Co.,Ltd.


• March 2021: Lupin partnered with pharmaceutical companies such as Sun Pharmaceutical Industries Ltd, Cadila Pharmaceuticals, and Torrent Pharmaceuticals Ltd. to acquire Pharmarack a B2B e-commerce platform, to enter the online pharmacy market.

REPORT COVERAGE

The global report offers both qualitative and quantitative analysis of the global market, including a comprehensive examination of market size and growth rates across various segments. Additionally, the report includes market dynamics and the competitive landscape, providing key insights such as disease prevalence in different regions, industry advancements, pipeline analysis, regional analysis, alternative treatment methods for hemorrhoids, and the influence of COVID-19 on the market.

Report Scope & Segmentation

ATTRIBUTE	DETAILS
Study Period	2019-2032
Base Year	2023
Estimated Year	2024
Forecast Period	2024-2032
Historical Period	2019-2022
Growth Rate	CAGR of 6.1% from 2024 to 2032
Unit	Value (USD billion)
Segmentation	By Product Type Suppository Sprays Creams & Ointments Others
By Drug Class Non-steroidal Anti-inflammatory Drugs (NSAIDs) Local Anesthetics Corticosteroids Others
By Type Internal External
By Distribution Channel Hospital Pharmacy Drug Store and Retail Pharmacy Online Pharmacy
By Region North America (By Product Type, By Drug Class, By Type, By Distribution Channel, By Country) U.S. Canada Europe (By Product Type, By Drug Class, By Type, By Distribution Channel,  and By Country/ Sub-Region) U.K. Germany France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Product Type, By Drug Class, By Type, By Distribution Channel,  and By Country/ Sub-Region) China Japan India Australia Southeast Asia Rest of Asia Pacific Latin America (By Product Type, By Drug Class, By Type, By Distribution Channel,  and By Country/ Sub-Region) Brazil Mexico Rest of Latin America Middle East & Africa (By Product Type, By Drug Class, By Type, By Distribution Channel, and By Country/ Sub-Region) GCC South Africa Rest of Middle East & Africa